Business Context and Reporting Period
This Form 8-K is filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on July 12, 2023. The registrant is a Delaware corporation with its principal executive offices in Cambridge, MA. The company is listed on the Nasdaq Capital Market under the symbol LPTX and is classified as an emerging growth company.
Key Financial Metrics
This filing is a Current Report regarding specific corporate events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Regulatory Compliance: On July 7, 2023, the company received a Compliance Letter from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2). The company maintained a minimum bid price of at least $1.00 per share for 11 consecutive business days (June 21, 2023, to July 6, 2023), resolving a previous deficiency disclosed in November 2022.
- Clinical Trial Update: On July 12, 2023, the company announced the initiation of the Randomized Controlled Part B of the DeFianCe Study for its drug candidate DKN-01 in colorectal cancer patients.
Guidance, Outlook, and Risks
The filing incorporates a press release regarding the clinical trial initiation by reference but does not provide specific financial guidance, management commentary on future performance, or detailed risk factors within the body of this report. The primary risk addressed is the resolution of the stock price listing requirement.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for details on the DeFianCe Study design and timeline.
- Confirm the current stock price stability to ensure continued compliance with Nasdaq listing rules.
- Note that the company name in the metadata request ("Cypherpunk Technologies Inc.") is incorrect; the filing is for Leap Therapeutics, Inc.